Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

• Published in: Human vaccines & immunotherapeutics Vol. 8; no. 2; pp. 260 - 266
• Main Authors: Ikematsu, Hideyuki, Nagai, Hideaki, Kawashima, Masahiro, Kawakami, Yasunobu, Tenjinbaru, Kazuyoshi, Li, Ping, Walravens, Karl, Gillard, Paul, Roman, François
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.02.2012; Landes Bioscience
• Subjects: adjuvant; Adjuvants, Immunologic; Adult; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; AS03; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Cycle; Female; H1N1; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus - immunology; Humans; Influenza A Virus, H1N1 Subtype - immunology; Influenza Vaccines - administration & dosage; Influenza Vaccines - immunology; Influenza, Human - immunology; Influenza, Human - prevention & control; Japan; Landes; long-term; Male; Middle Aged; Organogenesis; pandemic; persistence; Proteins; Research Paper; Time Factors; Vaccination; Young Adult; Japan
• ISSN: 2164-5515; 2164-554X
• DOI: 10.4161/hv.18469

Background Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based Adjuvant System) administered 21 d apart was evaluated in Japanese adults [NCT00989612]. Methods One-hundred healthy subjects aged 20−64 y (stratified [1:1] into two age strata 20−40 y and 41−64 y) received 21 d apart, two doses of AS03-adjuvanted 3.75µg haemagglutinin (HA) H1N1 2009 vaccine. Immunogenicity data by haemagglutination inhibition (HI) assay six months after the first vaccine dose (Day 182) and microneutralization assay following each of the two vaccine doses (Days 21 and 42) and at Day 182 are reported here. Results Persistence of strong HI immune response was observed at Day 182 that met the US and European regulatory thresholds for pandemic influenza vaccines (seroprotection rate: 95%; seroconversion rate: 93%; geometric mean fold-rise: 20). The neutralizing antibody response against the A/Netherlands/602/2009 strain (antigenically similar to vaccine-strain) persisted for at least up to Day 182 (vaccine response rate: 76%; geometric mean titer: 114.4) and paralleled the HI immune response at all time points. No marked difference was observed in HI antibody persistence and neutralising antibody response between the two age strata. The vaccine had a clinically-acceptable safety profile. Conclusion Two priming doses of H1N1 2009 pandemic influenza vaccine induced an immune response persisting for at least six months after the first vaccine dose. This could be beneficial in evaluating the importance and effect of vaccination with this AS03-adjuvanted pandemic influenza vaccine.